Dale R. Pfost
Known title: Chief Executive OfficerCIK: 0001394663
Dale R. Pfost's purchase track record
Dale R. Pfost has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/14/2022 | CMMB | $10K | -15.4% | -13.4% | -1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMMB | ▲ Buy | Open Market | 1,800 | $7K | 3/14/2022 | View on chart |
| CMMB | ▲ Buy | Open Market | 700 | $3K | 3/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.